热门出版物 - 学术资源搜索

h5 指数:159
h5 中位数:243

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2017-2021 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#3 Oncology

标题/作者	引用次数	年份
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan Annals of Oncology 28, iv119-iv142	1584	2017
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China L Zhang, F Zhu, L Xie, C Wang, J Wang, R Chen, P Jia, HQ Guan, L Peng, ... Annals of Oncology 31 (7), 894-901	1337	2020
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, S Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237	1288	2018
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ... Annals of Oncology 28, iv1-iv21	1093	2017
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of Oncology 30 (8), 1194-1220	1090	2019
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up R Glynne-Jones, L Wyrwicz, E Tiret, G Brown, C Rödel, A Cervantes, ... Annals of Oncology 28, iv22-iv40	1061	2017
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ... Annals of Oncology 30 (5), 706-720	1017	2019
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56	1003	2019
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657	933	2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712	917	2017
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists HA Haenssle, C Fink, R Schneiderbauer, F Toberer, T Buhl, A Blum, ... Annals of Oncology 29 (8), 1836-1842	825	2018
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... Annals of Oncology 28 (1), 16-33	755	2017
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab N Chaput, P Lepage, C Coutzac, E Soularue, K Le Roux, C Monot, ... Annals of Oncology 28 (6), 1368-1379	702	2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ... Annals of Oncology 28, iv52-iv61	686	2017
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of Oncology 28 (8), 1713-1729	643	2017
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376	631	2017
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67	613	2018
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875	576	2019
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, ... Annals of Oncology 28, iv72-iv83	529	2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639	524	2017

1 - 20

计算机程序会自动估算并确定日期和引用次数。